Shopping Cart 0
Cart Subtotal
AED 0

Strongbridge Biopharma plc (SBBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Its KEVEYIS holds orphan drug designation in the US. Strongbridge Biopharma's pipeline products include COR-003 (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome; and COR-005 a novel somatostatin analog for the treatment of acromegaly with potential use in Cushing's syndrome and neuroendocrine tumors. The company also provides building franchise around rare endocrine disorders including product candidates for the treatment of endogenous Cushing's syndrome and acromegaly. Strongbridge Biopharma is headquartered in Trevose, Pennsylvania, the US.

Strongbridge Biopharma plc (SBBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13

Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15

Licensing Agreements 16

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17

Equity Offering 19

Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19

Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21

Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23

Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25

Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26

Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27

Strongbridge Biopharma Raises USD25 Million in IPO 29

Cortendo Raises USD33.2 Million in Private Placement of Shares 31

Cortendo to Raise USD33.2 Million in Private Placement of Shares 32

Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34

Cortendo Raises USD37.5 Million in Private Placement of Shares 35

Cortendo Raises USD11 Million in Private Placement of Shares 37

Cortendo Raises USD12.6 Million in Private Placement of Shares 38

Cortendo Raises USD2.1 Million in Private Placement of Shares 39

Cortendo Raises USD0.7 Million in Private Placement of Shares 40

Cortendo Raises USD3.1 Million in Private Placement of Shares 41

Strongbridge Biopharma plc-Key Competitors 42

Strongbridge Biopharma plc-Key Employees 43

Strongbridge Biopharma plc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 45

Financial Announcements 45

Aug 08, 2018: Strongbridge Biopharma reports second quarter 2018 financial results and provides corporate update 45

May 10, 2018: Strongbridge Biopharma Reports First Quarter 2018 Financial Results and Provides Corporate Update 47

Mar 12, 2018: Strongbridge Biopharma Announces Full-Year 2017 Financial Results 49

Nov 14, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Third Quarter 2017 Financial Results 51

Aug 07, 2017: Strongbridge Biopharma Provides Updates on KEVEYIS Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results 54

May 16, 2017: Strongbridge Biopharma Provides Corporate Update and Reports First Quarter 2017 Financial Results 57

Mar 27, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Full-Year 2016 Financial Results 59

Clinical Trials 61

Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome 61

Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis 62

Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome 63

Other Significant Developments 64

Sep 25, 2017: Strongbridge Biopharma Launches the Uncovering Periodic Paralysis Genetic Testing Program 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13

Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17

Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19

Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21

Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23

Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25

Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26

Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27

Strongbridge Biopharma Raises USD25 Million in IPO 29

Cortendo Raises USD33.2 Million in Private Placement of Shares 31

Cortendo to Raise USD33.2 Million in Private Placement of Shares 32

Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34

Cortendo Raises USD37.5 Million in Private Placement of Shares 35

Cortendo Raises USD11 Million in Private Placement of Shares 37

Cortendo Raises USD12.6 Million in Private Placement of Shares 38

Cortendo Raises USD2.1 Million in Private Placement of Shares 39

Cortendo Raises USD0.7 Million in Private Placement of Shares 40

Cortendo Raises USD3.1 Million in Private Placement of Shares 41

Strongbridge Biopharma plc, Key Competitors 42

Strongbridge Biopharma plc, Key Employees 43

Strongbridge Biopharma plc, Subsidiaries 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Strongbridge Biopharma plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company's marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Its KEVEYIS holds orphan drug designation in the US. Strongbridge Biopharma's pipeline products include COR-003 (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome; and COR-005 a novel somatostatin analog for the treatment of acromegaly with potential use in Cushing's syndrome and neuroendocrine tumors. The company also provides building franchise around rare endocrine disorders including product candidates for the treatment of endogenous Cushing's syndrome and acromegaly. Strongbridge Biopharma is headquartered in Trevose, Pennsylvania, the US.

Strongbridge Biopharma plc (SBBP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13

Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15

Licensing Agreements 16

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17

Equity Offering 19

Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19

Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21

Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23

Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25

Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26

Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27

Strongbridge Biopharma Raises USD25 Million in IPO 29

Cortendo Raises USD33.2 Million in Private Placement of Shares 31

Cortendo to Raise USD33.2 Million in Private Placement of Shares 32

Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34

Cortendo Raises USD37.5 Million in Private Placement of Shares 35

Cortendo Raises USD11 Million in Private Placement of Shares 37

Cortendo Raises USD12.6 Million in Private Placement of Shares 38

Cortendo Raises USD2.1 Million in Private Placement of Shares 39

Cortendo Raises USD0.7 Million in Private Placement of Shares 40

Cortendo Raises USD3.1 Million in Private Placement of Shares 41

Strongbridge Biopharma plc-Key Competitors 42

Strongbridge Biopharma plc-Key Employees 43

Strongbridge Biopharma plc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 45

Financial Announcements 45

Aug 08, 2018: Strongbridge Biopharma reports second quarter 2018 financial results and provides corporate update 45

May 10, 2018: Strongbridge Biopharma Reports First Quarter 2018 Financial Results and Provides Corporate Update 47

Mar 12, 2018: Strongbridge Biopharma Announces Full-Year 2017 Financial Results 49

Nov 14, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Third Quarter 2017 Financial Results 51

Aug 07, 2017: Strongbridge Biopharma Provides Updates on KEVEYIS Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results 54

May 16, 2017: Strongbridge Biopharma Provides Corporate Update and Reports First Quarter 2017 Financial Results 57

Mar 27, 2017: Strongbridge Biopharma Provides Corporate Update and Reports Full-Year 2016 Financial Results 59

Clinical Trials 61

Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome 61

Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis 62

Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome 63

Other Significant Developments 64

Sep 25, 2017: Strongbridge Biopharma Launches the Uncovering Periodic Paralysis Genetic Testing Program 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Strongbridge Biopharma plc, Deals By Therapy Area, 2012 to YTD 2018 9

Strongbridge Biopharma plc, Medical Devices Deals, 2012 to YTD 2018 10

Strongbridge Biopharma plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Strongbridge Biopharma Acquires US rights to Keveyis from Taro Pharma 13

Strongbridge Biopharma Acquires Somatoprim from Aspireo Pharma 15

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 16

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 17

Strongbridge Biopharma Announces Partial Exercise of Underwriters Option of Public Offering of Shares for USD35.5 Million 19

Strongbridge Biopharma Raises USD25 Million in Public Offering of Shares 21

Strongbridge Biopharma Raises USD3 Million in Private Placement of Shares 23

Strongbridge Biopharma to Raise USD40 Million in Public Offering of Shares 25

Strongbridge Biopharma Plans to Raise Funds through Private Placement of Shares 26

Strongbridge Biopharma Raises USD35 Million in Private Placement of Shares and Warrants 27

Strongbridge Biopharma Raises USD25 Million in IPO 29

Cortendo Raises USD33.2 Million in Private Placement of Shares 31

Cortendo to Raise USD33.2 Million in Private Placement of Shares 32

Strongbridge Biopharma Raises USD26.4 Million in Private Placement of Shares 34

Cortendo Raises USD37.5 Million in Private Placement of Shares 35

Cortendo Raises USD11 Million in Private Placement of Shares 37

Cortendo Raises USD12.6 Million in Private Placement of Shares 38

Cortendo Raises USD2.1 Million in Private Placement of Shares 39

Cortendo Raises USD0.7 Million in Private Placement of Shares 40

Cortendo Raises USD3.1 Million in Private Placement of Shares 41

Strongbridge Biopharma plc, Key Competitors 42

Strongbridge Biopharma plc, Key Employees 43

Strongbridge Biopharma plc, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Strongbridge Biopharma plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.